Opinion: How a CT prescription drug bill would impair research
Paige Mahaney, Ph.D.
FacebookTwitterEmail
Boehringer Ingelheim’s U.S. headquarters in Ridgefield, Connecticut.Contributed photo
I lead Boehringer Ingelheim’s research team in Connecticut, and every day I witness our dedicated scientists striving to discover breakthrough treatments for patients. Our mission compels me to express Boehringer Ingelheim’s opposition to Gov. Ned Lamont’s proposal to set government price controls on prescription drugs (contained in House Bill 6447). The governor’s proposal will not help patients but instead, will hurt the ability of companies like ours to stay focused and invest in research to advance innovative new therapies.